



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

**MINUTES OF THE MEETING HELD ON WEDNESDAY 16TH OCTOBER 2019
AT 12.30pm**

**IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE,
ROYAL BLACKBURN HOSPITAL**

PRESENT:

Mr N Fletcher (NF)	Director of Pharmacy ELHT (Acting Chair)
Dr L Rogan (LR)	Associate Director of Medicines, Research and Clinical Effectiveness NHS EL CCG
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Dr T McKenzie	GP EL CCG
Mr U Akram	Pharmacist, Lancashire Care Foundation Trust

IN ATTENDANCE:

Ms L Prince	Medicines Management Technician EL CCG
-------------	--

2019/135: APOLOGIES:

Dr D Gavan (DG)	Consultant Radiologist ELHT
Dr K Burch (KB)	Consultant Microbiologist ELHT

2019/136: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2019/137: MINUTES OF AUGUST MEETING:

Accepted as a correct record.

2019/138: MATTERS ARISING:

From action sheet

2019/064: Formulary Updates - Tranexamic acid injection for topical use

Draft guidance for use of tranexamic acid has been produced by hospice pharmacist in conjunction with Palliative care team. Concerns were expressed that it is too long and not specific enough to topical use. SJ preferred a previous draft document that was presented on one page. VG to discuss with hospice pharmacist and revised document to come to next meeting.

**2019/098: LMMG Recommendations (From June LMMG)
Guidelines for the Prescribing of Nutritional Supplements Post Bariatric Surgery –**
Comments have been fed back to LMMG. Local guideline uploaded to website.

Riluzole Shared Care Guideline - Comments have been fed back to LMMG.

**2019/099: LMMG Recommendations (From July LMMG)
Testosterone Shared Care Guideline** - Comments have been fed back to LMMG

2019/106: Hospital Admissions Checklist – Updated – ongoing, meeting with care home team arranged.

2019/125: New Product Request – Farco-Fill® Protect – Polly Harris, Community Matron in attendance for this item. This product is requested for use in the continence service for selected patients with catheters that require frequent use of catheter maintenance solutions and frequent changes of the catheter, even though they are designed to last for 12 weeks. ELMMB supports a trial of the use of Farco-Fill® Protect for selected patients whose catheters currently only last for a very short period. District Nurses to get an assessment from the clinical team before requesting it to be prescribed.
Resolved: ELMMB support a trial of the use of Farco-Fill® Protect.

**2019/128: Formulary Updates –
Aminophylline tablets –** used in primary care, add to formulary as option.

Traffic light: GREEN

Capsacin cream – Not currently available – option to direct patients to OTC alternatives in the meantime. It will remain on formulary.

2019/131: Treatment of Vitamin B12 Deficiency Draft – A local audit has been undertaken by local biochemist which demonstrated almost 80% tests resulted in no required interventions. LR to arrange a meeting with biochemist to agree pathway in line with local thresholds and feedback to group.

Action: LR to arrange meeting with biochemist and feedback outcomes.

Not from action sheet:

2019/129: SPS Guide: DOAC Dosing In Renal Impairment

SJ expressed concern that the SPS guide did not make it clear the dose reductions only applied to the AF indication for DOAC's.

2019/093: New Product Request – Lanreotide – Dr J Collum (JC), Consultant Gastroenterologist in attendance. Requested to use lanreotide depot injections to manage patients with multiple gastrointestinal bleeding episodes, refractory to treatment, that require several blood transfusions a year. JC described successful use in an individual patient resulting in a reduction in the number of blood transfusions and reducing acute hospital admissions. Although treatment is unlicensed and would be very expensive it would be less expensive than multiple hospital admissions and blood transfusions.

This request was clinically supported for up to 5 patients with a review after 3-6 months treatment to assess effectiveness. Funding options via directorate / specialist commissioning will need to be explored before commencement. NF will discuss with finance.

Action: NF to explore funding for a maximum of 5 patients

2019/095: New Product Request – Parathyroid hormone (Natpar®) – LMMG have advised this is NHSE commissioned for specialist endocrinology. NF to discuss with finance & NHSE to establish if ELHT is classed as specialist endocrinology and be able to be reimbursed for the drug expenses. Concerns expressed that Natpar has not been approved by SMC due to safety issues.

Action: NF to attain clarity over whether ELHT is a specialist centre and can claim for Natpar from NHSE

2019/139: NEW PRODUCT REQUEST – OCTENILIL WOUND IRRIGATION

Application withdrawn – will reapply with revised information.

2019/140: NEW PRODUCT REQUEST – NUTRIZYM 22® CAPSULES

Nutrizym 22® requested by dieticians/gastroenterology as an second line option when patients requiring pancreatic enzymes are intolerant to creon®. ELMMB agreed to add to formulary.

Resolved: Nutrizym 22® added to formulary as a second line option when intolerant to Creon® **Traffic light: AMBER**

2019/141: NEW PRODUCT REQUEST - KETOTIFEN UNIT DOSE EYE DROPS

Ketotifen unit dose eye drops (Ketofall®) requested by Mr Usmani, Consultant ophthalmologist, for seasonal allergic conjunctivitis, as an option when combined antihistamine and mast cell stabilising properties are required. There are no comparisons included to topical mast cell stabilizers and oral antihistamines used together. Ketofall® was not supported by ELMMB and is not approved for formulary

Action: Ketofall® will not be added to formulary. Traffic light: BLACK

2019/142: LMMG CONSULTATIONS (for Nov LMMG)

Pathway for prevention of stroke & systemic embolism in NVAf – comment that DOAC has been changed to NOAC and on page 7 estimation of renal function information is contradictory.

Fidaxomicin New Medicine Assessment – supported.

Stiripentol New Medicines Assessment – supported.

Testosterone Shared Care Guideline updated – monitoring section requires testosterone to state fasting level, guideline supported.

Guideline for Antihyperglycaemic therapy in Type 2 Diabetes - updated - supported

Resolved: Comments to be sent to LMMG

2019/143: LMMG Recommendations (From Sept LMMG)

Ciclosporin (Verkazia[®]) eye drops New Medicine Recommendation – accepted as written for ELHE. **Traffic light: AMBER**

Dymista[®] New Medicine Recommendation – accepted as written for ELHE. **Traffic light: BLACK**

Vitamin D Position Statement – updated – acknowledged.

Guidelines for Home Monitoring of Blood Glucose Levels – updated – acknowledged. ELHE will continue to use local guidelines.

Psoriasis: Biologic & High Cost Drug Commissioning Pathway – updated – accepted as written for ELHE.

ADHD Shared Care Guideline – updated – accepted as written for ELHE. SJ expressed concerns that it is not being implemented in line with guideline with regards to monitoring and prescribing responsibilities. Paediatric pharmacist to discuss with clinicians.

Action: VG to ask paediatric pharmacist to follow up compliance with shared care with clinicians.

Gender Dysphoria Trans Female Patient Information Leaflet – updated – accepted as written for ELHE.

Camouflage Products position Statement – Amend for ELHE. Remove section on products that are not reimbursed.

2019/144: FORMULARY UPDATES

Trihexphenidyl liquid – to be included on formulary as it is used for dystonic symptoms in children with neurodevelopment conditions. **Traffic light: AMBER**

Resolved: Formulary to be updated as above

2019/145: ELHT: ADULT ANTIMICROBIAL GUIDE

Lower GI Surgery – updated

Teicoplanin Dosing and Monitoring advice - added

Resolved: Lower GI surgery and Teicoplanin sections of Adult Antimicrobial Guide acknowledged.

2019/146: MEDICINES FOR MINOR HEALTH CONDITIONS LEAFLET

Leaflet to support self-care. The 'What if my symptoms don't improve' section to be amended before uploading to website as a resource.

Leaflet for Changes to rubefaciants prescribing acknowledged and for upload to website.

Resolved: Leaflets to support self-care acknowledged.

2019/147: DRY EYE – PATIENT INFORMATION LEAFLET

Leaflet to support self-care of dry eyes. Remove reference to omega 3 & 7 and keep line as eat a healthy diet, then upload to website

Action: Dry Eye Leaflet to support self-care acknowledged.

2019/148: BISPHOSPHONATES FOR OSTEOPOROSIS RESOURCES

Resources from PrescQIPP to support the use of bisphosphonates for the treatment of osteoporosis acknowledged. To be uploaded to website as a resource.

Resolved: Resources to support use of bisphosphonates acknowledged.

2019/149: NICE RECOMMENDATIONS (from Sept)

Sodium zirconium cyclosilicate for treating hyperkalaemia [TA599] is recommended as an option by NICE. Approved in line with NICE.

CCG Commissioned

Traffic Light: RED

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer [TA600] is recommended as an option by NICE. Approved in line with NICE.

Cancer Drugs Fund

Traffic Light: RED

Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal) (TA601)

Traffic Light: BLACK

Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA602)

Traffic Light: BLACK

Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) (TA603)

Traffic Light: BLACK

Benralizumab for treating severe eosinophilic asthma (TA565 updated) is recommended as an option by NICE. Approved in line with NICE.

Traffic Light: RED

STANDING ITEMS

2019/150: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA MEDICINES MANAGEMENT GROUP (LSCMMG) MINUTES - September 2019

Minutes acknowledged

2019/151: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – August 2019

Minutes acknowledged

**2019/152: FOR ACTION/INFORMATION: LANCASHIRE CARE FOUNDATION TRUST
D & T COMMITTEE MINUTES – September 2019**

Minutes acknowledged

**DATE OF NEXT MEETING – Wednesday 20th November 2019 12.30pm, Seminar
Room 5, Learning & Development Centre, RBH.**

Please note meetings have reverted back to 12.30pm – 2pm

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 16TH OCTOBER 2019

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2019/064	Formulary Updates – Tranexamic acid – guidance from palliative care team to come to be revised for next meeting	VG	Nov 19
2019/093	New Product Request – Lanreotide – funding options to be explored for specialist use in refractory gi bleeding	NF	Nov 19
2019/096	New Product request Parathyroid Hormone (Natpar®) – check with finance and NHSE if the ELHT endocrinology is considered to be ‘specialist endocrinology’ for reimbursement of drug expenses	NF	Nov 19
2019/106	Hospital Admissions Checklist – Updated – share with CCG Care Home Team and provide feedback.	LR	Oct 19
2019/131	Treatment Of Vitamin B12 Deficiency Draft – meeting arranged with biochemistry Consult with stakeholders and bring back revised guideline	LR LR/JV	Nov 19 Nov 19
2019/143	ADHD Shared Care Guideline Follow up the compliance with shared care with paediatric pharmacist	VG	Nov 19